- PLN66.67m
- PLN74.32m
- PLN145.51m
- 84
- 34
- 29
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 0.63% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.31 | ||
| Price to Tang. Book | 1.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.36 | ||
| EV to EBITDA | 23.1 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.47% | ||
| Return on Equity | 1.57% | ||
| Operating Margin | 1.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 30.82 | 30.49 | 61.61 | 81.08 | 145.51 | 51.9 | 61.6 | 35.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +6854.21 | +33.77 | +169.15 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
Directors
- Rafal Jelonek CSU
- Lukasz Urban CMG (47)
- Krzysztof Mikosz VSU
- Henryk Lewczuk VMG (57)
- Zaneta Homenda CAO
- Andrzej Mikosz MGB
- Michal Janik SUB
- Piotr Janowski SUB
- Kacper Krysiak SUB
- Tomasz Libera SUB
- Miroslaw Panek SUB
- Artur Wojcieszuk SUB
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- September 10th, 2008
- Public Since
- June 8th, 2010
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 4,193,118
- Address
- ul. Vetterow 5, LUBLIN, 20-277
- Web
- https://biomaxima.com/
- Phone
- +48 814408371
- Contact
- Lukasz Urban
- Auditors
- Grant Thornton Polska Sp. Z o.o. sp. k.
Upcoming Events for BMX
Similar to BMX
Bioceltix SA
Warsaw Stock Exchange
Biogened SA
Warsaw Stock Exchange
Cannabis Poland SA
Warsaw Stock Exchange
Celon Pharma SA
Warsaw Stock Exchange
Cosma SA
Warsaw Stock Exchange
FAQ
As of Today at 19:04 UTC, shares in BioMaxima SA are trading at PLN15.90. This share price information is delayed by 15 minutes.
Shares in BioMaxima SA last closed at PLN15.90 and the price had moved by -34.43% over the past 365 days. In terms of relative price strength the BioMaxima SA share price has underperformed the FTSE Global All Cap Index by -38.45% over the past year.
The overall consensus recommendation for BioMaxima SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
The BioMaxima SA dividend yield is 3.14% based on the trailing twelve month period.
Last year, BioMaxima SA paid a total dividend of PLN0.50, and it currently has a trailing dividend yield of 3.14%. We do not have any data on when BioMaxima SA is to next pay dividends.
We do not have data on when BioMaxima SA is to next pay dividends. The historic dividend yield on BioMaxima SA shares is currently 3.14%.
To buy shares in BioMaxima SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN15.90, shares in BioMaxima SA had a market capitalisation of PLN66.67m.
Here are the trading details for BioMaxima SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: BMX
Based on an overall assessment of its quality, value and momentum BioMaxima SA is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BioMaxima SA is PLN26.40. That is 66.04% above the last closing price of PLN15.90.
Analysts covering BioMaxima SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioMaxima SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -18.16%.
As of the last closing price of PLN15.90, shares in BioMaxima SA were trading -7.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BioMaxima SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN15.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BioMaxima SA's management team is headed by:
- Rafal Jelonek - CSU
- Lukasz Urban - CMG
- Krzysztof Mikosz - VSU
- Henryk Lewczuk - VMG
- Zaneta Homenda - CAO
- Andrzej Mikosz - MGB
- Michal Janik - SUB
- Piotr Janowski - SUB
- Kacper Krysiak - SUB
- Tomasz Libera - SUB
- Miroslaw Panek - SUB
- Artur Wojcieszuk - SUB